Cancers, Vol. 15, Pages 4478: Evaluation of Temozolomide and Fingolimod Treatments in Glioblastoma Preclinical Models
istan Rupp
Glioblastomas are malignant brain tumors which remain lethal due to their aggressive and invasive nature. The standard treatment combines surgical resection, radiotherapy, and chemotherapy using Temozolomide, albeit with a minor impact on patient prognosis (15 months median survival). New therapies evaluated in preclinical translational models are therefore still required to improve patient survival and quality of life. In this preclinical study, we evaluated the effect of Temozolomide in different models of glioblastoma. We also aimed to investigate the efficacy of Fingolimod, an immunomodulatory drug for m...
Source: Cancers - September 8, 2023 Category: Cancer & Oncology Authors: M élodie Davy Laurie Genest Christophe Legrand Oc éane Pelouin Guillaume Froget Vincent Castagn é Tristan Rupp Tags: Article Source Type: research
The CLARION study: first report on safety findings in patients newly initiating treatment with cladribine tablets or fingolimod for multiple sclerosis
Conclusion: No new safety signal was observed in patients treated with cladribine tablets, although results are limited by a relatively short duration of follow-up.PMID:37675878 | DOI:10.1080/03007995.2023.2256220 (Source: Herpes)
Source: Herpes - September 7, 2023 Category: Infectious Diseases Authors: Helmut Butzkueven Jan Hillert Merja Soilu-H änninen Tjalf Ziemssen Jens Kuhle Stig Wergeland Melinda Magyari Joseph R Berger Nicholas Moore Aida Aydemir Irene Bezemer Meritxell Sabid ó Source Type: research
The CLARION study: first report on safety findings in patients newly initiating treatment with cladribine tablets or fingolimod for multiple sclerosis
Conclusion: No new safety signal was observed in patients treated with cladribine tablets, although results are limited by a relatively short duration of follow-up.PMID:37675878 | DOI:10.1080/03007995.2023.2256220 (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - September 7, 2023 Category: Research Authors: Helmut Butzkueven Jan Hillert Merja Soilu-H änninen Tjalf Ziemssen Jens Kuhle Stig Wergeland Melinda Magyari Joseph R Berger Nicholas Moore Aida Aydemir Irene Bezemer Meritxell Sabid ó Source Type: research
The CLARION study: first report on safety findings in patients newly initiating treatment with cladribine tablets or fingolimod for multiple sclerosis
Conclusion: No new safety signal was observed in patients treated with cladribine tablets, although results are limited by a relatively short duration of follow-up.PMID:37675878 | DOI:10.1080/03007995.2023.2256220 (Source: Herpes)
Source: Herpes - September 7, 2023 Category: Infectious Diseases Authors: Helmut Butzkueven Jan Hillert Merja Soilu-H änninen Tjalf Ziemssen Jens Kuhle Stig Wergeland Melinda Magyari Joseph R Berger Nicholas Moore Aida Aydemir Irene Bezemer Meritxell Sabid ó Source Type: research
The CLARION study: first report on safety findings in patients newly initiating treatment with cladribine tablets or fingolimod for multiple sclerosis
Conclusion: No new safety signal was observed in patients treated with cladribine tablets, although results are limited by a relatively short duration of follow-up.PMID:37675878 | DOI:10.1080/03007995.2023.2256220 (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - September 7, 2023 Category: Research Authors: Helmut Butzkueven Jan Hillert Merja Soilu-H änninen Tjalf Ziemssen Jens Kuhle Stig Wergeland Melinda Magyari Joseph R Berger Nicholas Moore Aida Aydemir Irene Bezemer Meritxell Sabid ó Source Type: research
mRNA COVID-19 Vaccination Does Not Exacerbate Symptoms or Trigger Neural Antibody Responses in Multiple Sclerosis
In this study, mRNA COVID-19 vaccination was safe and did not exacerbate the autoimmune disease nor triggered neural autoantibodies or immune-mediated neurologic disorders. The outcome of patients who developed SARS-CoV-2 infection was favorable. (Source: Neurology Neuroimmunology and Neuroinflammation)
Source: Neurology Neuroimmunology and Neuroinflammation - September 7, 2023 Category: Neurology Authors: Blanco, Y., Escudero, D., Lleixa, C., Llufriu, S., Egri, N., Garcia, R. R., Alba, M., Aguilar, E., Artola, M., Aldea Novo, M., Alvarez, S., Caballero, E., Cabrera-Maqueda, J. M., Fonseca, E., Guasp, M., Hernando, A., Martinez-Hernandez, E., Olive-Cirera, Tags: All Immunology, Autoimmune diseases, COVID-19, Multiple sclerosis Research Article Source Type: research
Incidence and Characteristics of Melanoma in Multiple Sclerosis Patients Treated With Fingolimod: A Systematic Review
AbstractPurpose of ReviewThe treatment of multiple sclerosis has been revolutionised by disease-modifying therapies including fingolimod. However, these treatments are immunosuppressive and may be associated with increased risk and severity of skin cancer including melanoma. The aim of this review was to identify and evaluate the existing evidence regarding this relationship to help guide future patient counselling and screening practices. This systematic review involved a systematic search of the databases PubMed, EMBASE and Cochrane library, which was performed in July 2022.Recent FindingsThe initial search strategy iden...
Source: Current Dermatology Reports - August 30, 2023 Category: Dermatology Source Type: research
